Biography/Memoir

Wall street… tweaks

The analog of psilocybin that Gilgamesh is developing has been designed to eliminate the hallucinogenic experiences that are often set off by so-called magic mushrooms. Researchers working with the company [including team members from ATAI, Pfizer, Johnson & Johnson, etc], administer test drugs [new chemical entities] to mice and then capture their reactions using video…

READ MORE
Biography/Memoir

[Synthetic patented psilocybin] are giving [some stock] investors a bad trip

It won’t be long before politicians trip together to resolve their differences… billionaire German investor Christian Angermayer, says. Right now, though, the charm offensive isn’t working so well. An exchange-traded fund tracking psychedelic stocks has lost two-thirds of its value since peaking last year. While some of these companies haven’t suffered as much… the comedown…

READ MORE
Biography/Memoir

Compass… updates on [synthetic polymorph] psilocybin…

Compass sinks after depression therapy results… the net loss for the year [2021] was $71.7 million…  …Compass doesn’t have any meaningful revenue… continues to explore… indications and therapeutic approaches… there were 12 people in the [synthetic psilocybin polymorph] study… who exhibited suicidal behavior or thoughts, or who showed intent to harm themselves. Original Article (Green Market…

READ MORE
Politics

…Compass Pathways’… patent…

Compass will now have three months to respond to each filing. Then, the Patent Trial and Appeal Board, a collection of administrative judges… will make a decision as to whether the petitioner demonstrates that at least one of the challenged claims is “more likely than not” unpatentable—and whether the case should proceed to a trial.…

READ MORE
Biography/Memoir

DEA to increase psilocybin… production for research purposes

The United States Drug Enforcement Administration (“DEA”) has proposed an increase in the manufacture… psilocin and psilocybin for clinical trial and research purposes… stated that its objective was to assist in the development of new federally approved therapies. …increased its production goals for psilocin and psilocybin, which are the main psychoactive components of magic mushrooms. Initially, the…

READ MORE
Biography/Memoir

[Compass Patent GB2572023B]… health

The right to use psychedelic[s] is currently navigating through the legislature, with places like Oregon, Washington DC, [et al.] decriminalizing psychedelic plant-based drugs… A revolution is sweeping mental health. Not since President Nixon declared war on drugs have researchers and traditional practitioners been able to share the results. The early data shows that plant-based therapy…

READ MORE
Science

…psychedelics boost brain growth factor levels?

Brain-derived neurotrophic factor (BDNF) regulates neuronal development and survival and triggers adaptive neuroplasticity… animal studies have reported that acute and chronic administration of various psychedelic compounds, including LSD, psilocybin, DMT, and other ayahuasca-derived alkaloids, can increase BDNF production and neurogenesis (the formation of new neurons). Importantly, threats to our well-being such as stress, ageing and…

READ MORE